Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Respiratory Aspiration 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 35Cisplatin 26Blood Specimen Collection 25durvalumab 17Paclitaxel 17osimertinib 15Radiosurgery 15Bevacizumab 15Radiotherapy 14Nivolumab 14Gemcitabine 14atezolizumab 13Biopsy 13Drug Therapy 12Docetaxel 11130-nm albumin-bound paclitaxel 11Immunoglobulin G 10X-Rays 9Taxes 9Standard of Care 9Practice Guidelines as Topic 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × Inhalation × Clear all
NCT06896890 2025-03-26

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

Inhatarget Therapeutics

Phase 1/2 Recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Aspiration

Data powered by HemOnc (CC BY 4.0) Colophon âš¡